An interventional study of Deka SmartXide Touch C60 (MonaLisa Touch) and Sham in Recurrent Urinary Tract Infection and Genitourinary Syndrome of Menopause, sponsored by King's College Hospital NHS Trust. Active, not recruiting at 1 site in United Kingdom. Open to female participants. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by King's College Hospital NHS Trust · Not applicable, Interventional, and Treatment
Recurrent urinary tract infection (rUTI) is a common and difficult to treat problem with limited treatment option; postmenopausal women are disproportionately affected. The genitourinary syndrome of menopause (GSM) describes the broad spectrum of signs and symptoms caused by the loss of endogenous sex steroids. The combined effects of urogenital epithelial tissue thinning and changes to the vaginal and bladder microbiome can predispose to ascending UTIs. Recurrent UTIs is a component of GSM.
Intravaginal laser therapy has been shown to be safe and effective for the treatment of GSM, however, the role of laser for treatment of recurrent UTIs is unknown. We hypothesis that the incidence of UTI will be reduced as CO2 laser restores vaginal epithelium to a state similar to that of a pre-menopausal woman, preventing microtrauma, and increases Lactobacillus and normal flora (Athanasiou et al., 2016). Lactobacillus is considered the bacteria that helps keep the vagina healthy and infection free through its production of lactic acid which lowers vaginal pH, this more acidic environment may be protective from uropathogens.
We therefore aim to conduct a single-blinded, multi-centre, randomised controlled trial comparing the use of intravaginal CO2 laser therapy to sham in post-menopausal women with rUTIs and to determine the impact on the microbiome.
Urinary tract infections (UTIs) are the most common outpatient infection with a prevalence of 20% in women over 65, compared with 11% in the overall population (Chu and Lowder, 2018).
The genitourinary syndrome of menopause (GSM) is the accepted term used to describe the broad spectrum of genitourinary tract symptoms and signs caused by the loss of endogenous sex steroids that occurs at the time of and after the menopause. Global improvements in healthcare have resulted in an aging population. Today women are spending 40% of their lives in the postmenopausal state with 50-70% of postmenopausal women reporting symptomatic GSM. The combined effects of urogenital epithelial tissue thinning and changes to the vaginal and bladder microbiome can predispose to ascending UTIs. Recurrent UTIs is a component of GSM.
Current interventions for recurrent urinary tract infections in women include lifestyle and behavioural advice, complimentary therapies and antibiotics. These treatment regimens are not always effective or acceptable. Intravaginal Laser therapy is an alternative non-hormonal treatment of GSM as it stimulates tissue repair and restores normal vaginal function.
Currently intravaginal laser therapy has been shown to be safe and effective for the treatment of GSM, as described in a recent network analysis of 29 randomised controlled studies, incorporating 8311 patients (Li et al., 2021). Provisional results using FemTouch®, fractional CO2 laser, appear promising with 9/12 (75%) of post-menopausal women UTI free at 12 months follow-up (Yang and Foley). However, there is a scarcity of studies available looking at the impact of this novel technology for the treatment of recurrent UTIs.
The investigators aim to conduct a single-blinded, randomised controlled trial comparing the use of intravaginal CO2 laser therapy to sham in post-menopausal women with rUTIs and to determine the impact on the microbiome. The investigators hypothesise that this treatment will be effective in reducing the incidence of urinary tract infection as CO2 laser through a process of thermomodulation, simulates tissue repair by restoring vaginal epithelium to a state similar to that of a pre-menopausal woman. In addition, a study assessing the effect of micro-ablative functional CO2 laser reported an increase in Lactobacillus and normal flora (Athanasiou et al., 2016). Lactobacillus is considered the bacteria that helps keep the vagina healthy and infection free through its production of lactic acid which lowers the vaginal pH, this more acidic environment may be protective from uropathogens. The role and impact of Laser on other microbial communities is still not fully understood, this study aims to expand this knowledge base.
Recurrent UTIs is a common and difficult to treat problem with limited treatment options, this study endeavors to expand the knowledge pool and provide alternative non-pharmacological options using this novel technology.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 48 is below the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →King's College Hospital NHS Trust is the lead sponsor of 164 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch) will be administered intravaginally over a course of 5 cycles
Device: Deka SmartXide Touch C60 (MonaLisa Touch)
Sham treatment -Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
Device: Sham
Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)
Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
To determine and compare the incidence of symptomatic antibiotic-treated UTI during the 6-month follow-up period after completion of allocated treatment
Determined from the UTI history diary and cross-referenced with hospital and GP records
Time frame: 6 months
UTI history diary
Participants will be given a UTI history diary to complete which will documents all symptomatic and treated UTI, the diary will be cross-referenced with participant history and review of medical history at each follow-up appointment.
Time frame: 18 months
Vaginal Health Index Score (VHIS)
o It incorporates a clinical examination of the vagina for pH, elasticity, fluid volume, epithelial integrity, moisture. Vaginal pH will be obtained using a piece of litmus paper placed on the lateral wall of the vagina.
Time frame: 18 months
King's Health Questionnaire (KHQ)
21 items about urinary tract symptoms yield scores in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep/energy \& severity of symptoms).
Time frame: 18 months
International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS)
A 12 item questionnaire for evaluating female lower urinary tract symptoms
Time frame: 18 months
International Consultation on Incontinence Questionnaire - Vaginal Symptoms (ICIQ-VS)
A 14 item questionnaire for evaluating vaginal symptoms, associated sexual matters and impact on quality of life (QoL)
Time frame: 18 months
10 cm Visual Analogue Scale for Symptoms (VAS)
Consists of a 10cm line, used to determine intensity of symptoms with two endpoints representing 0 ("no symptoms" and 10 ("symptom at the worse it could be"). Symptoms assessed: vaginal dryness, dyspareunia, itching, burning, dysuria, frequency, urgency, overall symptoms
Time frame: 18 months
Urinary Tract Infection Symptom Assessment Questionnaire (UTISA)
14-item questionnaire asking about the severity and bothersome of seven key UTI symptoms.
Time frame: 18 months
Female Sexual Function Index Scoring (FSFI)
A 19 item questionnaire designed to measure sexual functioning in women.
Time frame: 18 months
Health Service Utilisation Questionnaire (HSU-Q)
An instrument for the standardized and systematic assessment of various aspects of health care utilisation
Time frame: 18 months
Treatment satisfaction questionnaire for laser (TSQ-L)
A modified 10-item questionnaire used to determine participant satisfaction with treatment
Time frame: 18 months
Vulvoscopic Genital Tissue Appearance Scale (VGTA)
assesses 10 parameters of the appearance of the genital tissue including loss of labia minora/majora, decreased glans clitoris, stenosis of introitus, prominence of the urethral meatus, vestibular pallor, vestibular pallor, vesicular erythema, loss of vaginal rugae, loss of vestibular moisture and loss of prominence of the anterior vaginal wall. A score of 0 to 30 is obtained, the higher the score the worse the vulvoscopic genital tissue appearance
Time frame: 18 months
Adverse event recording
Adverse events will be asked at each visit and participant will have contact details to reports any throughout the study period
Time frame: 18 months
Dipstick urine analysis
Reagent strips used to detect substances in urine including nitrate, leucocytes, glucose, protein, pH, ketones and blood
Time frame: 18 months
Standard urine culture
Routine urinalysis that identify bacteria or yeast causing a urinary tract infection
Time frame: 18 months
Expanded Quantitative Urine Culture (EQUC)
- EQUC uses larger urine volume, longer incubation times, multiple growth media and atmospheric conditions and enables species-level identification
Time frame: 18 months
16S rRNA rapid Next-generation Gene Sequencing
16S rRNA NGS provide gene-level information for species. It utilises PCR amplification and NGS of essential 16S ribosomal RNA genes. It enables the evaluation of even closely related bacterial species through evolutionary polymorphisms
Time frame: 18 months
Shotgun metagenomic sequencing
allows the identification and profiling of microbial species independent of reference sequences.
Time frame: 18 months
Plan to share: Undecided — Will be available at request
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
King's College Hospital NHS Trust